β-Amyloid accumulation in the human brain after one night of sleep deprivation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 17, 2018, Pages 4483-4488

  Shokri Kojori, Ehsan ^a   Wang, Gene Jack ^a   Wiers, Corinde E ^a   Demiral, Sukru B ^a   Guo, Min ^a   Kim, Sung Won ^a   Lindgren, Elsa ^a   Ramirez, Veronica ^a   Zehra, Amna ^a   Freeman, Clara ^a   Miller, Gregg ^a   Manza, Peter ^a   Srivastava, Tansha ^a   De Santi, Susan ^b   Tomasi, Dardo ^a   Benveniste, Helene ^c   Volkow, Nora D ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b Piramal Enterprises Limited   (India)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer s disease; Beta amyloid; Glymphatic system; Hippocampus; Sleep

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; FLORBETABEN; APOE PROTEIN, HUMAN;

ADULT; ADVERSE OUTCOME; AGED; ALZHEIMER DISEASE; APOE GENE; ARTICLE; BRAIN REGION; FEMALE; GENETIC RISK; GENOTYPE; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; MALE; MOOD CHANGE; NIGHT SLEEP; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PRIORITY JOURNAL; PROTEIN METABOLISM; SLEEP DEPRIVATION; SUBCORTEX; THALAMUS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; GENETICS; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; FEMALE; GENOTYPE; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SLEEP DEPRIVATION; THALAMUS;

EID: 85045873784     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1721694115     Document Type: Article

References (71)

1. Nedergaard M (2013) Neuroscience. Garbage truck of the brain. Science 340: 1529–1530.
2. Mestre H, Kostrikov S, Mehta RI, Nedergaard M (2017) Perivascular spaces, glymphatic dysfunction, and small vessel disease. Clin Sci (Lond) 131:2257–2274.
3. Xie L, et al. (2013) Sleep drives metabolite clearance from the adult brain. Science 342: 373–377.
4. Kang J-E, et al. (2009) Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle. Science 326:1005–1007.
5. Tabuchi M, et al. (2015) Sleep interacts with aβ to modulate intrinsic neuronal excitability. Curr Biol 25:702–712.
6. Spira AP, et al. (2013) Self-reported sleep and β-amyloid deposition in community-dwelling older adults. JAMA Neurol 70:1537–1543.
7. Brown BM, et al.; AIBL Research Group (2016) The relationship between sleep quality and brain amyloid burden. Sleep (Basel) 39:1063–1068.
8. Sprecher KE, et al. (2015) Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiol Aging 36:2568–2576.
9. Ju Y-ES, et al. (2013) Sleep quality and preclinical Alzheimer disease. JAMA Neurol 70: 587–593.
10. Ju Y-ES, Lucey BP, Holtzman DM (2014) Sleep and Alzheimer disease pathology—A bidirectional relationship. Nat Rev Neurol 10:115–119.
11. Mucke L, Selkoe DJ (2012) Neurotoxicity of amyloid β-protein: Synaptic and network dysfunction. Cold Spring Harb Perspect Med 2:a006338.
12. Jagust W (2016) Is amyloid-β harmful to the brain? Insights from human imaging studies. Brain 139:23–30.
13. Spira AP, Gottesman RF (2017) Sleep disturbance: An emerging opportunity for Alzheimer’s disease prevention? Int Psychogeriatr 29:529–531.
14. Lee H, et al. (2015) The effect of body posture on brain glymphatic transport. J Neurosci 35:11034–11044.
15. Iliff JJ, et al. (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 4:147ra111.
16. Ooms S, et al. (2014) Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: A randomized clinical trial. JAMA Neurol 71:971–977.
17. LaFerla FM, Green KN (2012) Animal models of Alzheimer disease. Cold Spring Harb Perspect Med 2:a006320.
18. Bu XL, et al. (October 31, 2017) Blood-derived amyloid-β protein induces Alzheimer’s disease pathologies. Mol Psychiatry, 10.1038/mp.2017.204.
19. Deane R, Zlokovic BV (2007) Role of the blood-brain barrier in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 4:191–197.
20. Wei M, et al. (2017) Sleep deprivation induced plasma amyloid-β transport disturbance in healthy young adults. J Alzheimers Dis 57:899–906.
21. Lucey BP, et al. (December 8, 2017) Effect of sleep on overnight CSF amyloid-β kinetics. Ann Neurol, 10.1002/ana.25117.
22. Klunk WE, et al. (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 55:306–319.
23. Rowe CC, et al. (2008) Imaging of amyloid β in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurol 7:129–135.
24. Fodero-Tavoletti MT, et al. (2012) In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer. Nucl Med Biol 39:1042–1048.
25. Villemagne VL, et al. (2011) Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 52:1210–1217.
26. Sabri O, Seibyl J, Rowe C, Barthel H (2015) Beta-amyloid imaging with florbetaben. Clin Transl Imaging 3:13–26.
27. Ni R, Gillberg P-G, Bergfors A, Marutle A, Nordberg A (2013) Amyloid tracers detect multiple binding sites in Alzheimer’s disease brain tissue. Brain 136:2217–2227.
28. Yamin G, Teplow DB (2017) Pittsburgh compound-B (PiB) binds amyloid β-protein protofibrils. J Neurochem 140:210–215.
29. Schuff N, et al.; Alzheimer’s Disease Neuroimaging Initiative (2009) MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers. Brain 132:1067–1077.
30. De Santi S, et al. (2001) Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22:529–539.
31. Mander BA, Winer JR, Jagust WJ, Walker MP (2016) Sleep: A novel mechanistic pathway, biomarker, and treatment target in the pathology of Alzheimer’s disease? Trends Neurosci 39:552–566.
32. Ju YS, et al. (2017) Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels. Brain 140:2104–2111.
33. Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of A β-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800.
34. Aron L, Yankner BA (2016) Neurodegenerative disorders: Neural synchronization in Alzheimer’s disease. Nature 540:207–208.
35. Bero AW, et al. (2011) Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci 14:750–756.
36. Cheng O, et al. (2015) Short-term sleep deprivation stimulates hippocampal neurogenesis in rats following global cerebral ischemia/reperfusion. PLoS One 10:e0125877.
37. Fernandes C, et al. (2015) Detrimental role of prolonged sleep deprivation on adult neurogenesis. Front Cell Neurosci 9:140.
38. Castellano JM, et al. (2011) Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 3:89ra57.
39. Jack CR, Jr, et al.; Alzheimer’s Disease Neuroimaging Initiative (2010) Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease. Brain 133: 3336–3348.
40. Vandenberghe R, et al. (2010) 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 68:319–329.
41. Meyer-Luehmann M, et al. (2008) Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease. Nature 451:720–724.
42. Condello C, Schain A, Grutzendler J (2011) Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. Sci Rep 1:19.
43. Rothman SM, Herdener N, Frankola KA, Mughal MR, Mattson MP (2013) Chronic mild sleep restriction accentuates contextual memory impairments, and accumulations of cortical Aβ and pTau in a mouse model of Alzheimer’s disease. Brain Res 1529: 200–208.
44. Zhao HY, et al. (2017) Chronic sleep restriction induces cognitive deficits and cortical beta-amyloid deposition in mice via BACE1-antisense activation. CNS Neurosci Ther 23:233–240.
45. Camus V, et al. (2012) Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 39:621–631.
46. Montagne A, et al. (2015) Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85:296–302.
47. Cai Z, Hussain MD, Yan L-J (2014) Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease. Int J Neurosci 124:307–321.
48. Zhu B, et al. (2012) Sleep disturbance induces neuroinflammation and impairment of learning and memory. Neurobiol Dis 48:348–355.
49. Sehlin D, et al. (2016) Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer’s disease. Nat Commun 7:10759.
50. Wu JC, et al. (2006) Frontal lobe metabolic decreases with sleep deprivation not totally reversed by recovery sleep. Neuropsychopharmacology 31:2783–2792.
51. Ma N, Dinges DF, Basner M, Rao H (2015) How acute total sleep loss affects the attending brain: A meta-analysis of neuroimaging studies. Sleep (Basel) 38:233–240.
52. Bullich S, et al. (2017) Validation of non-invasive tracer kinetic analysis of 18F-florbeta-ben PET using a dual time-window acquisition protocol. J Nucl Med jnumed.117.200964.
53. Price JL, Drevets WC (2010) Neurocircuitry of mood disorders. Neuropsychopharmacology 35:192–216.
54. Mueller AD, Meerlo P, McGinty D, Mistlberger RE (2013) Sleep and adult neurogenesis: Implications for cognition and mood. Sleep, Neuronal Plasticity and Brain Function, eds Meerlo P, Benca RM, Abel T (Springer, Heidelberg, Germany), pp 151–181.
55. Dissel S, et al. (2017) Enhanced sleep reverses memory deficits and underlying pathology in Drosophila models of Alzheimer’s disease. Neurobiol Sleep Circadian Rhythms 2:15–26.
56. Glasser MF, et al.; WU-Minn HCP Consortium (2013) The minimal preprocessing pipelines for the Human Connectome Project. Neuroimage 80:105–124.
57. Catafau AM, et al. (2016) Cerebellar amyloid-β plaques: How frequent are they, and do they influence 18F-florbetaben SUV ratios? J Nucl Med 57:1740–1745.
58. Bullich S, et al. (2017) Optimal reference region to measure longitudinal amyloid-beta change with 18F-florbetaben PET. J Nucl Med jnumed.116.187351.
59. Heurling K, Buckley C, Van Laere K, Vandenberghe R, Lubberink M (2015) Parametric imaging and quantitative analysis of the PET amyloid ligand [(18)F]flutemetamol. Neuroimage 121:184–192.
60. Ossenkoppele R, Prins ND, van Berckel BN (2013) Amyloid imaging in clinical trials. Alzheimers Res Ther 5:36.
61. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6: 279–287.
62. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153–158.
63. Logan J, et al. (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834–840.
64. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 28:193–213.
65. Choe YM, et al. (2016) Sleep quality in young and middle age-period is associated with cerebral amyloid burden in cognitively normal elderly people. Alzheimers Dement 12(Suppl):P171–P172.
66. Westwood AJ, et al. (2017) Prolonged sleep duration as a marker of early neuro-degeneration predicting incident dementia. Neurology 88:1172–1179.
67. Liu C-C, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 9:106–118, and erratum (2013), 10.1038/ nmeurol.2013.32.
68. Reiman EM, et al. (2005) Correlations between apolipoprotein E e4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA 102:8299–8302.
69. Corneveaux JJ, et al. (2010) Association of CR1, CLU and PICALM with Alzheimer’s disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet 19:3295–3301.
70. Friston KJ, et al. (1995) Analysis of fMRI time-series revisited. Neuroimage 2:45–53.
71. Poline J-B, Worsley KJ, Evans AC, Friston KJ (1997) Combining spatial extent and peak intensity to test for activations in functional imaging. Neuroimage 5:83–96.